Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab

Схожие документы

• Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab
  по: Callahan, Margaret K, et al.
  Опубликовано: (2013)
• Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer
  по: Rajan, Arun, et al.
  Опубликовано: (2014)
• Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
  по: Gettinger, Scott N., et al.
  Опубликовано: (2015)
• Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma
  по: Larkin, James, et al.
  Опубликовано: (2015)
• Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
  по: Callahan, Margaret K., et al.
  Опубликовано: (2018)